At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 21 enrolled
Drug / intervention
Talazoparib Tosylatedrug
Likely dose
Talazoparib Tosylate 1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Clinical Trial of the PARP Inhibitor Talazoparib in BRCA1 and BRCA2 Wild Type Patients With Advanced Triple Negative Breast Cancer and Homologous Recombination Deficiency or Advanced HER2 Negative Breast Cancer or Other Solid Tumors With a Mutation in Homologous Recombination Pathway Genes
In Brief
A Phase 2 clinical trial evaluating Talazoparib Tosylate for Advanced Breast Cancer and 2 related conditions. Completed, enrolled 21 participants across 1 site.
Detailed Summary
The aim of this single-arm phase 2 clinical trial is to evaluate the anti-cancer activity of Talazoparib (also known as BMN 673) in patients with advanced breast cancer with specific genetic or tumor genomic alterations. Patients with either triple-negative or HER2-negative breast cancer are eligible.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsBioMarin Pharmaceutical, Pfizer
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 2015
Enrollment StartAug 2015
Primary CompletionDec 2019
Study CompletionDec 2022
TodayJul 2026
First PostedMar 27, 2015
Enrollment StartAug 1, 2015
Primary CompletionDec 23, 2019
Study CompletionDec 1, 2022
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 11.3 years ago
Interventions
Talazoparib Tosylatedrug
Participants receive Talazoparib tosylate at 1 mg by mouth daily.